Get the Daily Brief
Latest Biotech News
Breakthroughs in Malaria Control via Mosquito Gene Editing
Innovations in gene editing have yielded a promising new approach to combat malaria transmission. Scientists at UC San Diego and Johns Hopkins University developed a CRISPR-Cas9 allele-drive...
Funding Dynamics in Biotech Amid Market Uncertainties
The biotech sector faces a more cautious investment environment following a period of exuberance during the COVID-19 pandemic. Venture capital is flowing more selectively, favoring companies with...
Advances in Immunotherapy and Oncology Platforms
New immunotherapies and targeted therapies are progressing rapidly through clinical stages and launching innovative platforms. Janux Therapeutics presented promising pipeline data for autoimmune...
Regulatory and Market Developments in Diagnostics and Therapeutics
The FDA granted approval for Geneoscopy’s updated stool collection kit for its ColoSense RNA-based colorectal cancer screening test, designed to improve patient compliance. Roche Diagnostics...
New Therapeutics and Trials in Autoimmune and Inflammatory Diseases
Novel drug candidates and therapies targeting autoimmune and inflammatory conditions advance clinical development. Abivax SA’s obefazimod, a first-in-class miRNA-enhancing oral drug for ulcerative...
Corporate Restructuring and Leadership Changes in Biotech
Several biopharmaceutical companies continue to undergo restructuring to optimize focus amid challenging market conditions. Rocket Pharmaceuticals cut 30% of staff while narrowing its gene therapy...
Research on Human Genomics and Structural Variations
New long-read sequencing studies offer an unprecedented view into human genomic complexity. The University of Washington-led 1000 Genomes Project Long-Read Sequencing Consortium expanded its...
Elevidys Gene Therapy Crisis Hits Duchenne Patients
Sarepta Therapeutics' Duchenne muscular dystrophy gene therapy Elevidys remains embroiled in controversy following its FDA accelerated approval in June 2023. The therapy, priced at $3.2 million,...
Dispatch Bio Launches Universal Solid Tumor Immunotherapy
Dispatch Bio, a biotech startup founded in 2022, officially launched with $216 million in funding, including backing from CAR-T pioneer Carl June. The company’s technology platform, named Flare,...
AI-Designed Protein Binders Enhance Precision Immunotherapy
Researchers led by Nobel Laureate David Baker at the University of Washington have developed artificial intelligence methods to design protein binders targeting peptide-MHC complexes, enabling...
1000 Genomes Project Advances with Long-Read Sequencing Data
The 1000 Genomes Project Long-Read Sequencing Consortium has expanded its efforts by integrating PacBio data alongside nanopore sequencing to generate comprehensive genetic variation maps. This...
Abivax Ulcerative Colitis Drug Surges on Positive Phase 3 Results
Abivax’s experimental miRNA-124 enhancer, obefazimod, demonstrated significant clinical remission and response in two Phase 3 trials for moderately to severely active ulcerative colitis. The 50 mg...
Thermo Fisher Beats Q2 Expectations, Raises 2025 Guidance
Thermo Fisher Scientific exceeded Q2 2025 revenue and earnings estimates, driven by strong growth in life sciences solutions and laboratory products segments. The company increased full-year...
AstraZeneca’s Gefurulimab Clears Phase 3 in Myasthenia Gravis
AstraZeneca reported positive Phase 3 PREVAIL trial outcomes for gefurulimab, a self-administered C5 complement inhibitor for anti-acetylcholine receptor antibody-positive generalized myasthenia...
New Genetic Strategy Halts Malaria Transmission in Mosquitoes
A Nature-published study describes a CRISPR-Cas9 editing approach that changes a single amino acid in the FREP1 gene of Anopheles mosquitoes, rendering them unable to transmit malaria without...
FDA Launches National Priority Voucher for Accelerated Review
The FDA initiated the Commissioner’s National Priority Voucher (CNPV) pilot program to expedite drug review times to 1–2 months for therapies addressing designated U.S. health priorities,...
Dispatch Bio Unveils $216M Solid Tumor Immunotherapy Approach
Dispatch Bio launched with $216 million in funding and a novel immunotherapy platform aiming to target a broad range of solid tumors. The company’s technology uses a viral vector to deliver a...
Abivax’s Ulcerative Colitis Drug Soars After Phase 3 Wins
Abivax’s orally administered miRNA-124 enhancer, obefazimod, demonstrated significant clinical remission and response rates across large Phase 3 studies in moderately to severely active ulcerative...
FDA Extends Review on GSK’s Myeloma Drug Blenrep
The FDA has delayed its review deadline for GSK’s multiple myeloma drug Blenrep to October 23 to further evaluate additional data submitted by the company. This follows a negative advisory...
AI Advances Protein Design for Cancer Immunotherapy
Researchers led by Nobel Laureate David Baker have developed AI-driven design of highly specific protein binders that mimic T cell receptors targeting peptide-MHC complexes on diseased cells....